ALGERNON NEUROSCIENCE Trademark

Trademark Overview

On Thursday, July 6, 2023, a trademark application was filed for ALGERNON NEUROSCIENCE with the United States Patent and Trademark Office. The USPTO has given the ALGERNON NEUROSCIENCE trademark a serial number of 98072604. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Friday, June 6, 2025. This trademark is owned by Algernon Pharmaceuticals Inc.. The ALGERNON NEUROSCIENCE trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for treatment of brain injuries
algernon neuroscience

General Information

Serial Number98072604
Word MarkALGERNON NEUROSCIENCE
Filing DateThursday, July 6, 2023
Status653 - SUSPENSION LETTER - MAILED
Status DateFriday, June 6, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and Servicespharmaceutical preparations for treatment of brain injuries
NOT AVAILABLE"NEUROSCIENCE"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, August 6, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAlgernon Pharmaceuticals Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressVancouver, BC V6C1G8
CA

Trademark Events

Event DateEvent Description
Monday, July 10, 2023NEW APPLICATION ENTERED
Sunday, August 6, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 18, 2024ASSIGNED TO EXAMINER
Wednesday, March 20, 2024NON-FINAL ACTION WRITTEN
Wednesday, March 20, 2024NON-FINAL ACTION E-MAILED
Wednesday, March 20, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, June 19, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, June 19, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, June 19, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 4, 2025SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Thursday, February 6, 2025NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Thursday, February 6, 2025SUSPENSION INQUIRY WRITTEN
Monday, May 5, 2025TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, May 19, 2025ASSIGNED TO LIE
Thursday, June 20, 2024LETTER OF SUSPENSION E-MAILED
Thursday, June 20, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, June 20, 2024SUSPENSION LETTER WRITTEN
Thursday, February 6, 2025INQUIRY TO SUSPENSION E-MAILED
Wednesday, May 21, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 21, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, June 6, 2025LETTER OF SUSPENSION E-MAILED
Friday, June 6, 2025SUSPENSION LETTER WRITTEN
Friday, June 6, 2025NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

Related Keywords

neuroscience algernon injuries brain treatment preparations pharmaceutical